Thurston Springer Miller Herd & Titak Inc. Sells 18,349 Shares of Eli Lilly and Company $LLY

Thurston Springer Miller Herd & Titak Inc. reduced its position in Eli Lilly and Company (NYSE:LLY) by 96.2% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 722 shares of the company’s stock after selling 18,349 shares during the period. Eli Lilly and Company makes up approximately 1.1% of Thurston Springer Miller Herd & Titak Inc.’s investment portfolio, making the stock its 9th biggest position. Thurston Springer Miller Herd & Titak Inc.’s holdings in Eli Lilly and Company were worth $552,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Laurel Wealth Advisors LLC raised its position in shares of Eli Lilly and Company by 78,621.2% during the 2nd quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock valued at $9,005,392,000 after acquiring an additional 11,537,661 shares in the last quarter. Norges Bank bought a new position in Eli Lilly and Company in the 2nd quarter worth about $8,827,714,000. Vanguard Group Inc. grew its stake in shares of Eli Lilly and Company by 1.5% in the second quarter. Vanguard Group Inc. now owns 80,407,430 shares of the company’s stock worth $62,680,004,000 after purchasing an additional 1,183,038 shares in the last quarter. Assenagon Asset Management S.A. lifted its stake in shares of Eli Lilly and Company by 106.8% in the 2nd quarter. Assenagon Asset Management S.A. now owns 1,481,031 shares of the company’s stock worth $1,154,508,000 after acquiring an additional 765,010 shares during the period. Finally, Franklin Resources Inc. lifted its position in Eli Lilly and Company by 13.4% in the second quarter. Franklin Resources Inc. now owns 4,766,865 shares of the company’s stock worth $3,715,913,000 after purchasing an additional 564,736 shares during the period. Institutional investors own 82.53% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently weighed in on LLY shares. HSBC reissued a “hold” rating and issued a $1,070.00 target price on shares of Eli Lilly and Company in a research report on Wednesday, December 10th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Eli Lilly and Company in a research note on Monday, December 1st. JPMorgan Chase & Co. boosted their target price on shares of Eli Lilly and Company from $1,050.00 to $1,150.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 18th. BMO Capital Markets set a $1,200.00 price objective on shares of Eli Lilly and Company in a report on Thursday, December 4th. Finally, Wall Street Zen upgraded shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 1st. Four research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $1,141.73.

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $1,042.06 on Thursday. The company’s 50 day moving average price is $951.95 and its two-hundred day moving average price is $826.51. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,111.99. The company has a market capitalization of $985.14 billion, a P/E ratio of 50.98, a price-to-earnings-growth ratio of 1.32 and a beta of 0.37. The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.24 and a current ratio of 1.55.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The company had revenue of $17.60 billion for the quarter, compared to the consensus estimate of $16.09 billion. During the same period last year, the company earned $1.18 earnings per share. The firm’s revenue was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend is Friday, February 13th. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s payout ratio is presently 29.35%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.